Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.46
-10.3%		$0.58
$0.44
▼
$1.90
$4.51M4.91926,761 shs128,884 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-89.54%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-10.31%-6.42%-17.26%-31.91%-74.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.46
-10.3%		$0.58
$0.44
▼
$1.90
$4.51M4.91926,761 shs128,884 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-89.54%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-10.31%-6.42%-17.26%-31.91%-74.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
1.50
ReduceN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CLSD and RDHL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/3/2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$3.33M0.64N/AN/A($7.68) per share-0.05
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$290K13.95N/AN/A$0.83 per share0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$5.19N/AN/AN/A-665.19%N/A-124.15%N/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$430KN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.87
3.87
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.34
N/A

Institutional Ownership

CompanyInstitutional Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%

Insider Ownership

CompanyInsider Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
6.70%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
305.23 million4.89 millionOptionable
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2108.89 million8.28 millionNo Data

Recent News About These Companies

Redhill Biopharma (NASDAQ:RDHL) Shares Break Below 200-Day Moving Average - Should You Sell?
October 21 at 3:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31141571
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
October 19 at 8:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/2-9-million-nci-grant-awarded-for-clinical-development-of-redhills-opaganib-and-car-t-cell-combination-in-ultra-high-risk-multiple-myeloma-302912502.html
Redhill Biopharma (NASDAQ:RDHL) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31113588
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-operational-highlights-and-first-half-2026-financial-results-302894804.html
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/redhill-rdhl-acquires-rebyota-clenpiq-160630625.html
RedHill acquires rights to Ferring’s Rebyota and Clenpiq
September 1, 2026  |  thepharmaletter.comT
Redhill Biopharma stock doubles in one session — here's why
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/redhill-biopharma-stock-doubles-in-one-session-here-s-why/ar-AA2bhfIt
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
September 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/redhill-announces-transformational-acquisition-of-commercialization-rights-to-ferring-s-rebyota-and-clenpiq-1036510879
RedHill divests Talicia business to Apotex
September 1, 2026  |  thepharmaletter.comT
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
September 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-announces-transformational-acquisition-of-commercialization-rights-to-ferrings-rebyota-and-clenpiq-302866106.html
RedHill Biopharma Stock Surges 64% Over Deal To Divest Talicia Business
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3687115/redhill-biopharma-stock-surges-64-over-deal-to-divest-talicia-business.aspx
RedHill Biopharma (NASDAQ: RDHL) Soars to $1.60 - Monetizes Talicia Stake in $18 Million Cash Deal With Apotex
August 31, 2026  |  investorideas.comI
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-divests-talicia-to-apotex-for-18-million-cash-upfront-plus-milestones-to-fuel-strategic-growth-opportunities-302864832.html
Redhill Biopharma Ltd (NASDAQ: RDHL) - Share Price and Research
August 8, 2026  |  intelligentinvestor.com.auI
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
July 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ebola-cases-and-deaths-rapidly-mount---redhill-updates-on-opaganib-emergency-outbreak-development-302836392.html
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
June 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html
RedHill Biopharma announces up to $19.4M private placement
June 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/redhill-biopharma-announces-up-to-194m-private-placement/ar-AA25Xq2A
RedHill Biopharma Announces Up To $19.4 Million Private Placement
June 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html
RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak
June 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RDHL/pressreleases/2280827/redhill-biopharma-moves-to-advance-opaganib-as-oral-antiviral-option-for-current-ebola-outbreak/
RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
June 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68718281-redhill-biopharma-ltd-redhill-s-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan-drug-design-008.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$0.46 -0.05 (-10.31%)
Closing price 10/21/2026 03:58 PM Eastern
Extended Trading
$0.42 -0.03 (-7.47%)
As of 10/21/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas